LY-3300054
- Generic Name
- LY-3300054
A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors
- First Posted Date
- 2018-04-12
- Last Posted Date
- 2021-04-15
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 17
- Registration Number
- NCT03495323
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors
- Conditions
- Solid TumorNon Small Cell Lung CancerRenal Cell CarcinomaTriple Negative Breast Cancer
- Interventions
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2020-06-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 60
- Registration Number
- NCT03343613
- Locations
- 🇺🇸
IU Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸Tennessee Oncology PLLC, Nashville, Tennessee, United States
🇫🇷Gustave Roussy, Villejuif Cedex, France
A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors
- First Posted Date
- 2017-04-04
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 209
- Registration Number
- NCT03099109
- Locations
- 🇪🇸
Fundación Jiménez Díaz-Oncology, Madrid, Spain
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇰🇷Severance Hospital Yonsei University Health System, Seoul, Korea, Republic of
A Study of LY3200882 in Participants With Solid Tumors
- Conditions
- Solid Tumor
- Interventions
- Radiation: Intensity Modulated Radiotherapy
- First Posted Date
- 2016-10-18
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 223
- Registration Number
- NCT02937272
- Locations
- 🇦🇺
St Vincent's Hospital Sydney, Sydney, New South Wales, Australia
🇦🇺Greenslopes Private Hospital, Greenslopes, Queensland, Australia
🇫🇷CHRU de Lille, Lille, France
A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors
- Conditions
- Cutaneous MelanomaPancreatic CancerSolid TumorMicrosatellite Instability-High (MSI-H) Solid TumorsBreast Cancer (HR+HER2-)
- Interventions
- First Posted Date
- 2016-06-06
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 215
- Registration Number
- NCT02791334
- Locations
- 🇪🇸
Hospital Madrid Norte Sanchinarro, Madrid, Spain
🇨🇳National Cheng Kung University Hospital, Tainan, Taiwan
🇺🇸University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.